The Multiple Sclerosis Emerging Therapies Collaborative has published information sheets on the multiple sclerosis medication dextromethorphan hydrobromide and quinidine sulfate (DM/QS, also known as Nuedexta). The medication is approved to treat pseudobulbar affect (PBA). AAN members can access the sheets, which include known benefits and risks, as well as answers to commonly asked questions, at www.ms-coalition.org/EmergingTherapies.
The content is tailored to suit both clinicians and the public to facilitate effective communication and medical decision making. The AAN and MS Coalition members all have a stake in ensuring their constituencies receive the most accurate drug information, given there are a large number of competing information sources.
For more information, contact email@example.com.